Ignite Creation Date:
2024-07-17 @ 11:10 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06499480
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-07-05
Brief Title:
Italian Registry of Allergen ImmunoTherapy
Sponsor:
Società Italiana di Allergologia Asma e Immunologia Clinica
Organization:
Società Italiana di Allergologia Asma e Immunologia Clinica
Study Overview
Official Title:
Italian Registry of Patients With Allergic Disease and Treated With Allergen ImmunoTherapy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIAIT
Brief Summary:
RIAIT Italian Registry of Allergy Immunotherapy is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respiratory allergies rhinoconjunctivitis andor asthma in a real-life context through a network of allergy centers with specific interest and expertise in the management of allergic respiratory patients
Detailed Description:
Objectives include
Evaluate short and long-term real-life effectiveness and safety of AIT overall in specific patient groups phenotypes and with specific AIT products
Evaluate the pertinence and differences in suggesting AIT to a patient comparing physicians evaluation in various settings with established international guidelines describing the factors associated with treatment choices and changing over time and promoting interoperability data sharing and cross-comparison among centers
Describe long-term respiratory allergic disease evolution in patients treated with AIT
Describe the natural history of the patient population with respiratory allergies and identify patient groups describing their illness burden management patterns and clinical progression
Promote the creation of accurate standardized and efficient processes for diagnosing and treating respiratory allergic diseases especially with AIT
Assess biomarker data to predict diagnosis treatment response and long-term disease progression
Evaluate short and long-term real-life effectiveness and safety of AIT overall in specific patient groups phenotypes and with specific AIT products
Evaluate the pertinence and differences in suggesting AIT to a patient comparing physicians evaluation in various settings with established international guidelines describing the factors associated with treatment choices and changing over time and promoting interoperability data sharing and cross-comparison among centers
Describe long-term respiratory allergic disease evolution in patients treated with AIT
Describe the natural history of the patient population with respiratory allergies and identify patient groups describing their illness burden management patterns and clinical progression
Promote the creation of accurate standardized and efficient processes for diagnosing and treating respiratory allergic diseases especially with AIT
Assess biomarker data to predict diagnosis treatment response and long-term disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None